Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 4204.

https://doi.org/10.1182/blood-2019-126538

Published: 2019

Journal Articles

Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells

Manuela Mancini, PhD, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, MD, Michela Rondoni, MD, Maria Chiara Abbenante, MD, Luana Bavaro, Margherita Martelli, Roberta Zanotti, MD, Livio Pagano, MD, Michele Cavo, MD, Peter Valent, MD, Giovanni Martinelli, MD, Simona Soverini, PhD

Blood (2017) 130 (Supplement 1): 5290.

https://doi.org/10.1182/blood.V130.Suppl_1.5290.5290

Published: 2017

Journal Articles

Targeting WEE1 Kinase after G2/M Checkpoint Arrest Induces Apoptosis in Chronic Myeloid Leukemia Progenitors

Manuela Mancini, PhD, Sara De Santis, Cecilia Monaldi, Fausto Castagnetti, MD PhD, Luana Bavaro, Margherita Martelli, Gabriele Gugliotta, MD PhD, Gianantonio Rosti, MD, Elena Tenti, PhD, Maria Alessandr Santucci, MD, Michele Cavo, MD, Giovanni Martinelli, MD, Simona Soverini, PhD

Blood (2017) 130 (Supplement 1): 1588.

https://doi.org/10.1182/blood.V130.Suppl_1.1588.1588

Published: 2017

Journal Articles

The RET Receptor Tyrosine Kinase Promotes Acute Myeloid Leukemia through Protection of FLT3-ITD Mutants from Autophagic Degradation

Saskia Rudat, MSc, Anja Pfaus, MSc, Claudia Bühler, MD, Sophie Rabe, MSc, Lars Bullinger, MD, Stefan Gröschel, MD, Stephen M. Sykes, PhD, Michael D. Milsom, PhD, Jana M. Ellegast, MD, Stefan Fröhling, MD, Claudia Scholl, MD

Blood (2016) 128 (22): 2849.

https://doi.org/10.1182/blood.V128.22.2849.2849

Published: 2016

Journal Articles

The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia

Stefanie A. Hartsink-Segers, C. Michel Zwaan, Carla Exalto, Mirjam W.J. Luijendijk, Valerie S. Calvert, Emanuel F. Petricoin, PhD, William E. Evans, PharmD, Dirk Reinhardt, MD, Válerie de Haas, Maj Hedtjärn, Bo R. Hansen, PhD, Troels Koch, PhD, Huib N. Caron, Rob Pieters, MD, PhD, Monique L. Den Boer, PhD

Blood (2012) 120 (21): 1465.

https://doi.org/10.1182/blood.V120.21.1465.1465

Published: 2012

Journal Articles

In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1 .

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermaglia, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3388.

https://doi.org/10.1182/blood.V116.21.3388.3388

Published: 2010

Journal Articles

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

Jorge Cortes-Franco, MD, Hervé Dombret, MD, PhD, Philippe Schafhausen, MD, Tim H Brummendorf, MD, Nicolas Boissel, MD, PhD, Fabio Latini, MD, Laura Capolongo, Bernard Laffranchi, MD, Silvia Comis, MD

Blood (2009) 114 (22): 864.

https://doi.org/10.1182/blood.V114.22.864.864

Published: 2009

Journal Articles

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Tim H Brummendorf, MD, Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Melanie Braig, Imke Rohe, Edgar Jost, Oliver Galm, Carsten Bokemeyer, MD, Tessa Holyoake, Stefan Balabanov

Blood (2009) 114 (22): 1724.

https://doi.org/10.1182/blood.V114.22.1724.1724

Published: 2009

Journal Articles

Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors

Ron Paquette, MD, John Nicoll, Meenal Chalukya, Lukasz P Gondek, MD, PhD, Monika Jasek, Charles Sawyers, MD, Neil Shah, MD, PhD, Jaroslaw Maciejewski

Blood (2008) 112 (11): 575.

https://doi.org/10.1182/blood.V112.11.575.575

Published: 2008

Journal Articles

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Stefan Balabanov, MD/PhD, Artur Gontarewicz, MD, Gunhild Keller, MD, Jürgen Moll, PhD, Carsten Bokemeyer, MD, Tessa L Holyoake, MD/PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 3227.

https://doi.org/10.1182/blood.V112.11.3227.3227

Published: 2008

Journal Articles

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Stefan Balabanov, MD/PhD, Thoma Wilhelm, PhD, Simone Venz, PhD, Christine Barret, Gunhild Keller, MD, Mirja Bernhardt, Artur Gontarewicz, MD, Melanie Braig, PhD, Reinhard Walther, PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 336.

https://doi.org/10.1182/blood.V112.11.336.336

Published: 2008

Journal Articles

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Artur Gontarewicz, Stefan Balabanov, Gunhild Keller, Riccardo Colombo, Alessio Graziano, Enrico Pesenti, Daniel Benten, Carsten Bokemeyer, Walter Fiedler, Jürgen Moll, Tim H. Brümmendorf

Blood (2008) 111 (8): 4355–4364.

https://doi.org/10.1182/blood-2007-09-113175

Published: 2008

Journal Articles

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D., Gunhild Keller, M.D., Riccardo Colombo, Ph.D., Alessio Graziano, Ph.D, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.

Blood (2007) 110 (11): 1042.

https://doi.org/10.1182/blood.V110.11.1042.1042

Published: 2007

Journal Articles

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

Ronald L. Paquette, MD, Neil P. Shah, MD, PhD, Charles L. Sawyers, MD, Giovanni Martinelli, MD, Nicoll John, Meenal Chalukya, Maurizio Rocchetti, PhD, Carina Fiocchi, MD, Sylvia Comis, MD, Laura Capolongo, MD, Bernard Laffranchi, MD

Blood (2007) 110 (11): 1030.

https://doi.org/10.1182/blood.V110.11.1030.1030

Published: 2007

NARROW

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells

Targeting WEE1 Kinase after G2/M Checkpoint Arrest Induces Apoptosis in Chronic Myeloid Leukemia Progenitors

The RET Receptor Tyrosine Kinase Promotes Acute Myeloid Leukemia through Protection of FLT3-ITD Mutants from Autophagic Degradation

The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia

In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1 .

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only